A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy Participants

Inclusion Criteria: * Participants must be healthy males and females (INOCBP) * Participant must have Body mass index (BMI) of 18.0 kg/m2 through 32.0 kg/m2, inclusive. * Participant must have Body weight ≥ 50 kg Exclusion Criteria: * Participant must not have current or recent GI disease * Participant with evidence of organ dysfunction or any clinically significant deviation, as determined by investigator, from normal in physical examination, vital signs, 12-lead ECG, or clinical laboratory determinations beyond what is consistent with the target population. * Participant with prior exposure to BMS-986278 and exposure of any investigational drug or placebo within 4 weeks of study intervention administration. * Other protocol-defined Inclusion/Exclusion criteria apply.